Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease

Real-world evidence about mineralocorticoid receptor antagonist (MRA) use has been limited in chronic kidney disease, particularly regarding its association with hard renal outcomes. In this retrospective cohort study, adult chronic kidney disease outpatients referred to the department of nephrology...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2022-03, Vol.79 (3), p.679-689
Main Authors: Oka, Tatsufumi, Sakaguchi, Yusuke, Hattori, Koki, Asahina, Yuta, Kajimoto, Sachio, Doi, Yohei, Kaimori, Jun-Ya, Isaka, Yoshitaka
Format: Article
Language:English
Subjects:
Aged
Female
Glomerular Filtration Rate - drug effects
Humans
Kidney - drug effects
Kidney - physiopathology
Male
Middle Aged
Mineralocorticoid Receptor Antagonists - pharmacology
Mineralocorticoid Receptor Antagonists - therapeutic use
Original
Prognosis
Renal Insufficiency, Chronic - drug therapy
Renal Insufficiency, Chronic - mortality
Renal Insufficiency, Chronic - physiopathology
Retrospective Studies
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Real-world evidence about mineralocorticoid receptor antagonist (MRA) use has been limited in chronic kidney disease, particularly regarding its association with hard renal outcomes. In this retrospective cohort study, adult chronic kidney disease outpatients referred to the department of nephrology at an academic hospital between January 2005 and December 2018 were analyzed. The main inclusion criteria were estimated glomerular filtration rate ≥10 and
ISSN:0194-911X
1524-4563
DOI:10.1161/HYPERTENSIONAHA.121.18360